Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients (NCT05895123) | Clinical Trial Compass
CompletedPhase 2
Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients
Egypt80 participantsStarted 2021-11-01
Plain-language summary
STEMI is a serious type of coronary heart disease, which is a major cause of disability and death. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis .
Elevated serum LDL-cholesterol concentrations play a proatherogenic role by stimulating inflammation and oxidative processes.
Statins have been documented to retard fibrosis and ventricular hypertrophy by the cessation of myofibroblast activity. Clinical studies have proven that statins not only regulate lipids but also improve myocardial fibrosis, regulate cell proliferation and apoptosis, regulate ventricular remodeling, and protect the myocardium
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Electrocardiogram showed abnormal elevation of the ST segment.
✓. First myocardial infarction occurred.
✓. The patients received one-stage percutaneous coronary intervention (PCI) therapy within 12 h.
Exclusion criteria
✕. Severe cardiac insufficiency.
✕. Hepatic insufficiency (continuous increase of serum transaminase more than 3 times of the upper limit of normal level).